Voltron Therapeutics, INC

Investor Presentation – October 2022

Disclaimer and Safe Harbor

This document does not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This presentation is being provided for the sole purpose of providing the recipients with background information about Voltron's business. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment.

DISCLAIMER AND SAFE HARBOR

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

VOLTRON CORPORATE OVERVIEW

VOLTRON is a biotech company focused on bringing our Self-Assembling Vaccines (SAV) to patients with certain cancers or those at risk for infectious diseases.

Infectious pathogens

- Positive results in generating immunity against COVID-19 in recent animal testing recently reported

Immuno-Oncology

- Initially focused **on c**ervical, head & neck, and anal cancers
- New preclinical data show potent efficacy in E6/E7 related cancers

Initial proof of concept established in HPV cancers:

Oncology development well underway:

- ***Cervical Cancer – Continue work to file IND and proceed into Phase I trials***
- ***Prostate Cancer – PSCA model ready to begin***

Manufacturing scale-up in process; GMP material for first-in-man studies to be ready in 2023

FDA comments on IND pathway received and pathway confirmed

IND planned for 2023

Seasoned leadership team in place

Strong intellectual property position

VOLTRON THERAPEUTICS NEAR-TERM FINANCING PLAN

CURRENT BRIDGE ROUND	• $6 million bridge note • Converts into PubCo stock at a 25% discount to the next round • 8% interest, payable in stock
PUBLIC LISTING	• Prepare company to be publicly traded – Audit, IR Plan, necessary personnel • Prepare for 2Q 2023 NASDAQ listing

VOLTRON THERAPEUTICS RECENT PRGOGRESS

RECENT DEVELOPMENTS: VACCINE DEVELOPMENT & CORPORATE PROGRESS

1

Advanced animal work in Immuno-Oncology

- ***E6/E7 work demonstrated strong survival advantage***
- PSCA model to parallel this pathway with whole protein vaccine

2

FDA comments received on IND pathway

- **Pathway clear**
- Consistent with Voltron's proposed package

3

Progressed manufacturing scale-up of mtbHSP70

- Will be used in both Oncology & ID applications

6

SIGNIFICANT UNMET MEDICAL NEED

INFECTIOUS DISEASES GLOBALLY

- COVID-19 has had massive global impact; variants are likely to be seen
- Future emerging infectious diseases likely

CANCER IMMUNOTHERAPY

Cervical Global Cases/Year

570,000

Current Treatments include Surgery, Radiation, Chemotherapy, Targeted Therapy, and PD-1

Head and Neck Global Cases/Year

550,000

Current Treatments include Surgery, Radiation, Chemotherapy, PD-1

Anal Global Cases/Year

30,000

Current Treatments include Surgery, Radiation, Chemotherapy

Prostate Global Cases/Year

1,414,000

Current Treatments include Surgery, Radiation, Chemotherapy

VOLTRON THERAPEUTICS
A Lucius Partners Company
HARVARD
MGH 1811

VOLTRON PIPELINE



VOLTRON THERAPEUTICS
A Lucius Partners Company

INCREASED SURVIVAL: SAV CONFERRED A SIGNIFICANT SURVIVAL BENEFIT, VS PLACEBO & MAV ALONE





E6/E7 STUDY HIGHLIGHTS

The Primary Endpoints of The Study Were Met

- Overall Survival: eSAV had a highly significant and positive survival effect at 80, 130 and 215 µg per vaccine dose in the TC-1 tumor injected mice
- Tumor Volume Reduction: eSAV significantly reduced TC-1 tumor volume; with reduced tumor volume in 80, 130 and 215 µg eSAV receiving mice
- Dose Response: there was a dose-response to eSAV with the overall best survival benefit to the TC-1 tumor bearing mice at 215 µg eSAV
- Anti-mPD1 Combined Effect with SAV: There was no statistically significant difference among anti-mPD1 treated eSAV receiving mice compared to the matched anti-IgG2a treated group

Secondary endpoints

- Reactogenicity: eSAV is well tolerated. There was no reactogenicity observed

MANUFACTURING PROCESS

Drs. Zachary Shriver & Ishan Capila
to provide expertise in protein design, development and manufacturing; globally recognized expert in protein manufacturing

SCALE UP FOR PRODUCTION OF HSP70 IS PROCEEDING, and is now on a path to GMP production by 2023

PEPTIDE PRODUCTION progressing well and advancing to GMP level

BACK-UP SITES identified

VOLTRON THERAPEUTICS
A Lucius Partners Company
HARVARD
MGH 1811

VOLTRON TEAM

ORGANIZATION	KEY LEADERSHIP AND ADVISORS	
VOLTRON THERAPEUTICS	Anthony Zook; Executive Chairman	Fmr. CEO, AstraZeneca NA
	Pat Gallagher; CEO, Director	Management & Finance
	Matthew Duffy; President, Director	Management & Finance
	Paul Korner, MD; Director	Clinical Development
	Ishan Capila, PhD	Manufacturing & Protein Design
	Zachary Shriver, PhD; CSO, Visterra Inc.	Manufacturing & Protein Design
	Dr. Simon Pedder, Director	Fmr. Roche Oncology R&D
VIC AT MGH	Mark Poznansky, MD, PhD; Director, VIC	Infectious disease immunology, translational research
	Michael Callahan, MD, DTM&H (UK), MSPH; Director, Translational Research, VIC	Emerging infectious diseases, biological product development
	Jeff Gelfand, MD; Senior Scientist, VIC	Infectious diseases, SAV technology inventor

AFFINIVAX – INFECTIOUS DISEASE FOCUSED COMPANY

- Utilizes (validates) biotin avidin Binding
  - Also targeting programs with Klebsiella Pneumoniae, Staphylococcus Aureus, SARS-CoV-2, and Melanoma
  - GSK acquire Affinivax
  - $2.1 billion upfront and up to $1.2 billion in potential development milestone
    - Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS technology
  - Acquisition is expected to close in Q3 2022

- Pneumococcal Vaccine Market Size was valued at $8.16B and is projected to reach $12.17B by 2028 (5.15% CAGR)
  - Globally, approximately 150 million new cases of pneumonia occur annually among children younger than 5 years

VOLTRON THERAPEUTICS
A Lucius Partners Company
MGH 1811

NYKODE/GENETECH

- Genentech
  - (Oct. 2020) Genentech secured a global license to two neoantigen cancer vaccines developed by Vaccibody
  - Of interest to Voltron are the, VB10.16 cervical cancer vaccine, and the VB10.NEO therapeutic vaccine against solid tumors like melanoma, lung, bladder, renal, head and neck cancer
  - The agreement includes $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive global rights to DNA-based individualized neoantigen cancer vaccines based on VB10.NEO across multiple tumor types
  - VB10.NEO is a clinical-phase candidate that Vaccibody creates by identifying neoepitopes specific to a patient's tumor.
  - The agreement tasks Vaccibody with wrapping up phase 1b development of VB10.NEO, beyond which Genentech will take full control and bear all the costs

NYKODE/REGENERON

- (Nov 21) Vaccibody/Nykode signed a multi-license/collaboration deal with Regeneron Pharmaceuticals covering five vaccine programs – three for cancer and two for infectious diseases – which could each include several vaccine candidates
- Under the agreement, Nykode will be responsible for vaccine generation and characterization, while Regeneron will lead antigen identification, preclinical and clinical development, manufacturing and commercialization
- The total potential value of the deal stands at $925m plus royalties; Regeneron paid $30m upfront and invested $20m in the company at a premium of Nykode's share price. The latter is also potentially eligible for more than $875m in milestone payments, plus royalties on sales

VOLTRON CORPORATE OVERVIEW

VOLTRON is a biotech company focused on bringing our Self-Assembling Vaccines (SAV) to patients with certain cancers or those at risk for infectious diseases.

Infectious pathogens, such as COVID-19.

- Positive results in generating immunity against COVID-19 in recent animal testing recently reported

Specific cancers, particularly those related to human papilloma virus (HPV)

- New preclinical data show potent efficacy in E6/E7 related cancers

Initial proof of concept and experience:

- Lassa Fever and Q Fever, COVID-19: emerging infectious diseases, via MGH research

Oncology development well underway:

- *Potent activity in E6/E7 related cancer animal models*
- PSCA model ready to begin

Manufacturing scale-up in process; GMP material for first-in-man studies to be ready in 2023

FDA comments on IND pathway received and pathway confirmed

IND planned for 2023

Seasoned leadership team in place

Strong intellectual property position

VOLTRON THERAPEUTICS

Contact

Pat Gallagher, CEO
973-216-6014
pgallagher@luciuspartnersllc.com

Matthew Duffy, President
646-335-5923
mduffy@luciuspartnersllc.com